Tony Hagen


Findings Are Reported From De-escalation Therapy in Early Breast Cancer

December 15, 2021

Investigators said pathologic complete response was higher with a molecularly selected subgroup of patients with early-stage breast cancer treated with a nonchemotherapy combination that included a trastuzumab biosimilar.

EMA and WHO "Tailor" the Biosimilar Development Process

November 23, 2021

The European Medicines Agency (EMA) reports on progress to create a smoother, less wasteful biosimilar development process; and the World Health Organization (WHO) revises its biosimilar development guidelines.